Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations
- PMID: 17640862
- PMCID: PMC2892775
- DOI: 10.3324/haematol.11407
Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations
Abstract
Background and objectives: Functional characterization of heterozygous TERC (telomerase RNA component) and TERT (telomerase reverse transcriptase) mutations found in autosomal dominant dyskeratosis congenita (DC) and aplastic anemia (AA) shows that telomerase function is defective and that this is associated with short telomeres. This leads to reduced cell longevity with maximal impact on tissues with high proliferate potential. The aim of this study was to establish the role of TERC in the pathophysiology of uncharacterized patients with AA with some features of DC.
Design and methods: The TERC gene was screened for mutations by denaturing high performance liquid chromatography. To determine the functional significance of TERC mutations telomerase activity was assessed in an in vitro (TRAP) assay and telomere length of patients' samples was determined using Southern blot analysis. RESULTS This study led to the identification of four novel TERC mutations (G178A, C180T, D52-86 and G2C) and a recurrent TERC mutation (D110-113GACT).
Interpretation and conclusions: Two of the de novo TERC mutations (G178A and C180T) found uniquely produce a clinical phenotype in the first generation, differing from previously published cases in which individuals in the first generation are usually asymptomatic. Curiously these mutations are located near the triple-helix domain of TERC. We also observed that the recurrent D110-113GACT can present with AA, myelodysplasia or leukemia. The D52-86 is associated with varied phenotypes including pulmonary disease (pulmonary fibrosis) as the first presentation. In summary, this study reports the functional characterization of several novel TERC mutations associated with varied hematologic and extra-hematologic presentations.
Figures






Comment in
-
Dysfunctional telomeres and dyskeratosis congenita.Haematologica. 2007 Aug;92(8):1009-12. doi: 10.3324/haematol.11221. Haematologica. 2007. PMID: 17650438 No abstract available.
Similar articles
-
Heterozygous telomerase RNA mutations found in dyskeratosis congenita and aplastic anemia reduce telomerase activity via haploinsufficiency.Blood. 2004 Dec 15;104(13):3936-42. doi: 10.1182/blood-2004-05-1829. Epub 2004 Aug 19. Blood. 2004. PMID: 15319288
-
Genetic analyses of aplastic anemia and idiopathic pulmonary fibrosis patients with short telomeres, possible implication of DNA-repair genes.Orphanet J Rare Dis. 2019 Apr 17;14(1):82. doi: 10.1186/s13023-019-1046-0. Orphanet J Rare Dis. 2019. PMID: 30995915 Free PMC article.
-
Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure.Blood Cells Mol Dis. 2005 May-Jun;34(3):257-63. doi: 10.1016/j.bcmd.2004.12.008. Blood Cells Mol Dis. 2005. PMID: 15885610
-
Dyskeratosis congenita: molecular insights into telomerase function, ageing and cancer.Expert Rev Mol Med. 2004 Dec 20;6(26):1-23. doi: 10.1017/S1462399404008671. Expert Rev Mol Med. 2004. PMID: 15613268 Review.
-
Dyskeratosis congenita: the diverse clinical presentation of mutations in the telomerase complex.Biochimie. 2008 Jan;90(1):122-30. doi: 10.1016/j.biochi.2007.07.017. Epub 2007 Jul 31. Biochimie. 2008. PMID: 17825470 Review.
Cited by
-
The role of telomere biology in bone marrow failure and other disorders.Mech Ageing Dev. 2008 Jan-Feb;129(1-2):35-47. doi: 10.1016/j.mad.2007.11.002. Epub 2007 Nov 19. Mech Ageing Dev. 2008. PMID: 18160098 Free PMC article. Review.
-
The genetics of dyskeratosis congenita.Cancer Genet. 2011 Dec;204(12):635-45. doi: 10.1016/j.cancergen.2011.11.002. Cancer Genet. 2011. PMID: 22285015 Free PMC article. Review.
-
Revertant somatic mosaicism by mitotic recombination in dyskeratosis congenita.Am J Hum Genet. 2012 Mar 9;90(3):426-33. doi: 10.1016/j.ajhg.2012.01.004. Epub 2012 Feb 16. Am J Hum Genet. 2012. PMID: 22341970 Free PMC article.
-
Protein encoded in human telomerase RNA is involved in cell protective pathways.Nucleic Acids Res. 2018 Sep 28;46(17):8966-8977. doi: 10.1093/nar/gky705. Nucleic Acids Res. 2018. PMID: 30102362 Free PMC article.
-
Tieing together loose ends: telomere instability in cancer and aging.Mol Oncol. 2022 Sep;16(18):3380-3396. doi: 10.1002/1878-0261.13299. Epub 2022 Aug 16. Mol Oncol. 2022. PMID: 35920280 Free PMC article. Review.
References
-
- Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wiemann S, Mason PJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet. 1998;19:32–8. - PubMed
-
- Vulliamy T, Marrone A, Goldman F, Dearlove A, Bessler M, Mason PJ, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature. 2001;413:432–5. - PubMed
-
- Chen JL, Greider CW. Telomerase RNA structure and function: implications for dyskeratosis congenita. Trends Biochem Sci. 2004;29:183–92. - PubMed
-
- Marrone A, Dokal I. Dyskeratosis congenita: a disorder of telomerase deficiency and its relationship to other diseases. Expert Rev Derm. 2006;1:463–79.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical